4851 TAMIAMI TRAIL N, SUITE 200, NAPLES, FL
Enveric Biosciences Files Prospectus Supplement for $2.425 Million Shares
Investor Presentation
Enveric Biosciences Approves New Restricted Stock Unit Award Agreement
Reports Financial Results and Provides Corporate Update for First Quarter 2026
Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Financial Results, Press Release
Other Events
Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload